Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Add SHAREHOLDER in the return address
Try registered certified mail thru US Postal Service
Write your ideas and concerns via a registered postal letter to Boca Raton.
It will have to be signature signed by the receiver.
Your emails and phone calls are probably being filtered out as unknown and/or
shareholder put on hold, your only frustrating yourselves doing it this way.
Why keep trying that route...be different take it to a higher level.
I'd like to know if the traveling was business related and if it was to Israel/Brazil/plus wherever else
Anyone here willing to centralize something from other shareholders and compose something as
one opinion represented by many others might be a good thing
Rather see a global pharma. They are too small to get things moving expeditously. Also, a big pharma with money can run multiple trials of indication with varying dosages of the combination to improve chances for approval.
If so it better be for Merck CEO in Brazil...
https://br.linkedin.com/in/arnaud-coelho-94620453
"Just called and left Leo a message. His voicemail said to call him on WhatsApp since he is traveling and has poor reception but I left a message anyway."
Maybe we are in Israel again. BeaMed
https://www.timesofisrael.com/in-israel-everything-is-via-whatsapp-even-a-reality-tv-dating-show/#:~:text=If%20you%20want%20to%20reach,communication%20in%20the%20Jewish%20state.
Beamed cofounder Gil Shapira is CEO of neoLaser:
neoLaser in 1 years time progress:
June 2022
Gil owns and manages neoLaser, a company he founded in 2012, and led to revenue growth and profitability, with a 43% CAGR on its way to more than 1200 global installations and performing 50,000+ surgeries annually in over 30 countries.
June 2023
Gil owns and manages neoLaser, a company he founded in 2012, and led to revenue growth and profitability, with a 43% CAGR on its way to more than 1500 global installations and performing 70,000+ surgeries annually in over 30 countries.
Yeah, I figured he doesn't represent the guts of the company, so never contacted him.
I sure would like to know what the conversations were about between these well known
brain doctors in the USA, Israel and the StringRay company itself regarding what designs
and outcomes would make this machine top notch.
Have you contacted Beamed about
(price, performance, safety, cost efficiency, surgery time) vs Intuitive Davinci
Just curious, I asked them and got no reply and was only expecting one if lucky
private company for now
My guess would be minimum 500k for 1 machine.
Intuitive is selling davinci for 1 to 1.5 million.
Maybe the annual license fee approaches 100k yearly.
IPIX news (formerly Cellceutix)
Study Shows Cellceutix Antibiotic Active Against Drug-Resistant Superbug Klebsiella Pneumoniae
https://finance.yahoo.com/news/study-shows-cellceutix-antibiotic-active-103000797.html
https://www.usatoday.com/story/news/health/2023/06/08/klebsiella-pneumoniae-bacterial-outbreak-seattle-hospital/70301971007/
I will ask DeGrado about this Sun/Mon,
Give me some text form you would like me to send for him, I have communicated with him
previously.
Also, if you have questions about antiviral progress and/or interests?
I think the CEO lives near Palm Beach county Florida.
There are 44 billionaires in Palm Beach County Florida
Folks.... hit the business development section of IPIX website with this....
in whatever format you like.
Multiples of you get it thru multiple times, maybe the message
will get thru via a StringRay mode of action - laser etched in the head.
This will represent our current SHAREHOLDERS MEETING.
--------------------------------------------------------------------------------------------
Leo,
There are deep pockets in Palm Beach County Florida.
44 billionaires reside there.
I understand you have a home nearby.
I hope there are possibilities being pursued in that region to fund Brilacidin expansion -
the likes of OM, ABSSSI, Antiviral, Antifungal, Ulcerative Colitis
https://www.businessinsider.com/palm-beach-county-florida-migration-businesses-financial-services-new-york-2021-4
https://www.palmbeachpost.com/story/news/2021/10/06/palm-beach-trump-no-longer-forbes-400-real-time-billionaires-list-celebrities/6007002001/
How about the ...
Bill and Melinda Gates Foundation --- Brilacidin anti-viral help????
--------------------------------------------------------------------------------------------
We need to find partners for OM and antifungal and get back to the BUC pill and the previously planned 2A. Anything like >= 25% remission vs 5-8% placebo remission would be a good move forward.
Although Venezuelan equine encephalitis virus (VEEV) is a life-threatening pathogen with a capacity for epidemic outbreaks, there are no FDA-approved VEEV antivirals for humans.
https://pubs.acs.org/doi/abs/10.1021/acs.jpcb.3c00429
Again, your making a full blown assumption what Shina got as a reward
was major lickings. Maybe there was a stake, to WHAT EXTENT YOU
DON'T KNOW NOR I, BOTH SITTING REMOTELY AND UNINVOLVED
WITH IT.
TO INSINUATE IT MUST BE HUGE SO IT WAS KEPT QUIET IS YOUR OWN
THOUGHT GUESS. GOOD LUCK.
Firstly, they are providing a software service to fit the Beamed data into
a template software suite like they build for other imaged products. That
template will be further customized to fit Beamed's final product.
Certainly some reward would be a salaried contract, what extras who knows,
future license agreement if product FDA approved.
Is the CEO of the minority company (IPIX) allowed by the majority company (BEAMED)
to give full details of the transaction to the public. One would think not necessarily, at least not a rule.
IDTAI OK!!!
There is no definitive on the Shina and Beamed relationship as we know it. We don't know how much of Shina's current workload as a company is devoted to the Beamed project. The Shina work for Beamed...maybe its only 10% of Shina's current 2023 work budget and maybe Shina does get a small slice of Beamed. Nobody really knows.
If you have comms with the CEO maybe you can ask about NIH and sepsis, possible push forward??
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6615598/
A severe sepsis model that kills untreated infected mice at 2 d post infection was implemented for MRSA. The results showed that peptide analogs Pep16 and Pep19, at low repeated doses (0.5 mg.kg-1 per day), protected the infected animals (Fig 1H and 1I), whereas vancomycin—at an identical dose—was much less effective (Fig 1J). We directly compared our in vivo data to clinical-stage drug candidate brilacidin [20], which was injected on sets of 10 infected mice at multiple doses identical to those for Pep16 and Pep19. Brilacidin cured the infected animals at doses identical to those tested for Pep16 and Pep19. The differences between brilacidin and each of the two pseudopeptides were not statistically significant, but brilacidin tended to save more infected animals. These data indicated that Pep16 and Pep19 do compare well with this clinical-stage drug candidate.
My other question to them was, is Beamed's Shapira or Ekole the other cofounder of this cardiovascular heart failure company?
Don't know, emailed beamed 2 days ago. Doubt they will reply. I emailed them before about something (circular 360 degree laser coverage of tumors) and didn't hear from them.
View organization page for Incentive, Peregrine Ventures Incubator
Incentive, Peregrine Ventures Incubator
744 followers
3w
Position for a CEO and co-founder of a Cardiovascular startup Company
We are looking for an ambitious, energetic, and motivated executive scientist to lead a promising startup company for treating heart failure patients.
This is an opportunity with significant responsibility and considerable freedom to run a standalone operation touching all technical and commercial aspects of a startup company.
Required skills:
•Either Optical engineer, Electrical, Mechanical, or Physicist, Master's level education or above
•At least 5 years of experience in R&D project management and hands-on execution of R&D
•Team player with great communication, leadership, and negotiation skills
•Highly self-motivated, hands-on, can-do attitude, task-oriented individual
Advantages:
- Leading R&D developments through clinical trials
- Experience in regulatory interaction- e.g., submission package preparation, following regulatory guidelines, participating in regulatory meetings FDA/CE.
-Experience in IP management (writing/reviewing)
Responsibilities:
• Building the company strategic R&D work plan and preclinical studies
• Manage the company's R&D activities, including the performance of hands-on R&D tasks, hiring of skilled professionals and training them, as well as working with critical outside vendors
• Budget management - assessment of risk to eliminate resource and capital inefficiency, alongside astute budgetary allocation for R&D-oriented programs.
• Business Development and Alliance Management – constant market analysis to identify competitors' work and challenges while opening up new opportunities.
Please send CV's shapirag@beam-med.com
Perhaps they can try the BARDA route for ABSSSI, funds were given for ABSSSI as
noted in this link
https://www.genengnews.com/topics/drug-discovery/basilea-wins-additional-54-8m-barda-funding-to-develop-ceftobiprole-for-u-s/
My note was only of what soligenix had done for OM grants p2 and p3 regardless of the outcome your citing. I guess your injecting comedy.
Your welcome, thanks for citing it. Your concerns are real. We should care about any drugs out there that can help with a debilitating side effects of healthcare treatments.
I discovered Gil Shapira from beam-med.com (yes his contact address) is collecting resumes for a startup heart failure company. Have you by chance had any contact with beamed thru the email channels??
I relayed your idea in my own words of text this week thru the IPIX business development contact page on the website..
Maybe you can send your own thoughts in a better way than me thru the same contact point.
Another:
https://www.businesswire.com/news/home/20230223005456/en/Sinopia-Awarded-Grant-from-National-Institute-of-Dental-and-Craniofacial-Research-for-Oral-Mucositis
As well why is not the CEO working with NIH for grants with a Phase 3 BOM trial.
Soligenix got both Phase 2 and Phase 3 grants.
https://ir.soligenix.com/2020-06-24-Soligenix-Completes-Enrollment-in-its-Pivotal-Phase-3-Clinical-Trial-of-SGX942-for-the-Treatment-of-Oral-Mucositis
Soligenix has received partial funding from NIH for its oral mucositis clinical studies. The Phase 2 study was supported with a Phase I SBIR grant (#R43DE024032) award, with the Phase 3 study being supported by a Phase II SBIR grant (#R44DE024032) award.
They should have done mild to moderate to better their chances.
In my mind, idea is to prevent severe disease in those most susceptible.
With mild to moderate, better chance of partner.
ATEA as one example, did moderate and failed, I don't believe they did moderate to severe.
https://clinicaltrials.gov/ct2/show/NCT04396106
Brilacidin Activ trial, somewhat hopeful.
Hey, this one failed primary endpoint on Phase 2B data, but still going to an advanced stage 3 as part of govt Activ trial.
Shionogi’s NIH-backed COVID-19 treatment is advancing to late-stage testing after the FDA finalized the drug’s study design. The trial is part of the National Institutes of Health’s ACTIV-2 study, which has been exploring multiple potential COVID outpatient therapies since late 2020. So far, data on Shionogi’s treatment has been mixed : Interim phase 2a results found that the therapy, dubbed S-217622, significantly reduced viral load, but phase 2b data found no major change in clinical symptoms, chalking up a failure on the primary endpoint . Story
https://www.fiercepharma.com/pharma/covid-tracker-pfizer-biontech-moderna-vaccine-johnson-johnson-fda-booster-shot-antiviral
Keep in mind this Shionogi was for non-hospitalized - Activ2 outpatients, so perhaps the 2A did show reduction in viral load, because it was early in the virus stage.
IPIX SHOULD PURSUE MILD TO MODERATE, BOTH HOSPITALIZED AND NON_HOSPITALIZED.
Some ponderings...
What was the actual dosage amount for the P2?? as it was never listed on clinicaltrials.gov.
How many patients received a B+RDV combo.. were they all from the 2 USA sites?? this would only equate to maybe 12-14 patients (assuming 25 patients from 2 USA sites) if the 9 sites in Russia did most of the work. And how many of those 12-14 were moderate (6?) and how many severe (6?)? What can really be deduced from such a small # of patients if this is true? Perhaps a few were the early 3 day treatment only.
Why were a majority of the patients in this trial treated for severe covid? I would have preferred seeing a 70% moderate and 30% severe patient treatment. Antivirals need to be given as early as possible.
They tackled compassionate use, was the dosage amount the same for some CU patients as it was in the P2? Was Heparin in use for critical patients? Did the P2 trial kickoff and complete before the Degrado coronavirus work on Heparin was known? Why didn't GMU study the effect of Heparin?
There are non-Heparin drugs out there.
What daily frequency and dosage uppage was done in CU??
Was Brilacidin the only drug in CU use...monotherapy and
what could be seen?
Waiting for all these things to become more clear....
Regarding BOM, I want Leo to expand on what the reformulation would be in regards to better stickiness in the BOM oral spit and swish and would a 4 times per day swish and spit be considered??
Still better than receiving 5 IVs per week for 7 weeks as indicative of the other OM drug. I think the P2 was just Brilacidin with water 3X per day for 7 weeks.
It was a planned interim analysis and it happened as planned and fulfilled an interim safety analysis to decide whether dosage frequency increase. Did you expect more (efficacy) at 30 patients....
https://ir.cytokinetics.com/news-releases/news-release-details/cytokinetics-announces-completion-interim-safety-analysis
GOD BLESS YOU AND YOUR FAMILY.
YOUR IN MY PRAYERS.
TAKE CARE ALWAYS.
Hi,
With the Brilacidin+Remdesivir arm, will Brilacidin be escalated in dosage frequency when added to the Remdesivir, so that the combo has changed for some patients where Brilacidin+Remdesivir combo becomes say a 2*Brilacidin + Remdesivir combo after x # of days while some patients will stay on the original Brilacidin+Remdesivir combo for their whole treatment period?
Thnx (if you may know)
The 1 after any author name represents their employment at National Center for Biodefense and Infectious Diseases, George Mason University, Manassas, Virginia, 20110, USA
Thanks in regards to my communications.
Let you know if anything more is known.
Thanks Karin 4 your reply.
to me just recent.
Agree wholeheartedly, your a great patriot and protectorate.
Someone that gets it.
Remdesivir approval is not the end of the story.
Other trials combined with Remdesivir are being conducted right now.
This would be a give up on our country and the world by the FDA, not to pursue further either other combos or other drugs by themselves for find faster, more efficient therapies to reduce the seriousness of this virus and get us back to normal.
It's political nonsense.
https://www.statnews.com/2020/10/22/remdesivir-hefty-price-tag-ignores-nih-investment-in-its-creation/
The need to show something around election time.
C'mon FDA let's get some smart dollars allocated to better therapies than this. A global pandemic doesn't need big pharma interference for finding the best therapies.
BDD Pharma https://www.bddpharma.com/ - B-UC tablets.
https://veracerestaurant.com/
...
Islip, New York
Maybe veracaaaa sounds close to verasca close to vesca (what was originally written)
The doc should have explained himself better in that Trump was given oxygen twice, Friday and Saturday for a short bit of time as to ensure his oxygen levels made the climb back to normal as they were a little bit out of range. The liberal media spun things as if everything was out of control. DJT was not on constant and/or consistent oxygen treatments.
Can you private me tomorrow/Fri/weekend about something I want to share...maybe you have an alias somewhere else (other forum) as I don't have a premium subscription here...maybe Friday Happy Hour is still free here so I can PM you (but I think it isn't Happy Hour Friday PM anymore).
http://www.ipharminc.com/new-blog/2020/5/21/brilacidin-for-covid-19-proposed-targets-and-mechanisms-of-action-against-sars-cov-2
In news released on Tuesday, the Company announced that in vitro research being independently conducted at a U.S. Regional Biocontainment Laboratory (RBL) revealed Brilacidin reduced the viral titer (load) of SARS-CoV-2, the novel coronavirus responsible for COVID-19, by 75 percent as compared to vehicle control after only 1 hour of preincubation prior to infection. The concentration of Brilacidin tested was 10µM.
Whereas Brilacidin, prior to infection, has the potential both to disrupt the virus directly and prevent viral entry into host cells, in addition to inhibiting viral replication post-infection—making for three distinct potential direct antiviral mechanisms of action.